EE142 Cost-Effectiveness Analysis of Biosimilars Based Treatment Sequences for Moderate-to-Severe Crohn Disease in Spain

Crohn's disease (CD) yields a considerable burden to the Spanish National Health System (NHS). Thanks to the advent of adalimumab and infliximab biosimilars (bADA, bINF), costs burden decreased substantially. However, a further assessment on additional efficiencies is warranted. The NHS ’s Willingness to Pay (WTP) per additional Quality Adjusted Life Year (QALY) could be considered an important metric to assess.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research